Tremendous efforts have been and are being undertaken to achieve a successful transition of selective anti-cancer treatment modalities, particularly MEK inhibition and disruption of the PD-L1/PD-1 axis, from the promising preclinical stage to clinical trials and approval by medical authorities. The gene discussed is PDCD1; the disease is cancer.